NextEra Energy stock rises after Google power deal report
Investing.com - H.C. Wainwright has reiterated its Buy rating and $10.00 price target on Gossamer Bio Inc. (NASDAQ:GOSS) following a management meeting at the firm’s 27th Annual Global Investment Conference on September 9. The stock, currently trading at $3.18, has shown remarkable momentum with a 250% return year-to-date, while analyst targets range from $5 to $15. According to InvestingPro analysis, the stock appears fairly valued at current levels.
During the conference, Gossamer Bio management reintroduced seralutinib, an inhaled tyrosine kinase inhibitor targeting multiple receptors for the treatment of pulmonary arterial hypertension (PAH). The company emphasized seralutinib’s potential disease-modifying reverse-remodeling capabilities compared to standard vasodilator treatments. With a current market cap of $723 million and a strong liquidity position indicated by a 4.4x current ratio, the company maintains financial flexibility for its development programs. InvestingPro subscribers can access 12 additional key insights about GOSS’s financial health and growth prospects.
Gossamer Bio confirmed that its Phase 3 PROSERA trial features a 24-week six-minute walk distance primary endpoint and time to clinical worsening among key secondary endpoints. The company noted that the trial includes a sicker baseline patient mix, which could help detect meaningful treatment effects.
Top-line data from the PROSERA trial remains on schedule for February 2026, with H.C. Wainwright suggesting the 24-week primary endpoint should further de-risk the program.
The management team present at the conference included Chief Commercial Officer Bob Smith, Chief Financial Officer and Chief Operating Officer Bryan Giraudo, and Vice President of Corporate Finance and Communications Evan Belcher.
In other recent news, Gossamer Bio Inc . has garnered attention with several developments. UBS upgraded Gossamer Bio’s stock rating from Neutral to Buy, citing optimism surrounding the company’s Phase 3 pulmonary arterial hypertension (PAH) trial. The firm increased the price target from $1.25 to $9.00, highlighting an "underappreciated probability of success" for the seralutinib treatment. Meanwhile, H.C. Wainwright reiterated its Buy rating with a $10.00 price target, following a literature review that reinforced confidence in the potential of seralutinib. Cantor Fitzgerald also maintained its Overweight rating on the stock, noting improving investor sentiment as Gossamer Bio approaches a key data readout. These recent developments indicate a positive outlook from analysts regarding Gossamer Bio’s future prospects in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.